 | • レポートコード：MRC2-11QY00246 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はコレステロール降下薬のグローバル市場について調査・分析したレポートです。種類別（スタチン、コレステロール吸収阻害剤、フィブラート、PCSK9阻害剤）市場規模、用途別（病院、家庭、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別コレステロール降下薬の競争状況、市場シェア ・世界のコレステロール降下薬市場：種類別市場規模 2015年-2020年（スタチン、コレステロール吸収阻害剤、フィブラート、PCSK9阻害剤） ・世界のコレステロール降下薬市場：種類別市場規模予測 2021年-2026年（スタチン、コレステロール吸収阻害剤、フィブラート、PCSK9阻害剤） ・世界のコレステロール降下薬市場：用途別市場規模 2015年-2020年（病院、家庭、その他） ・世界のコレステロール降下薬市場：用途別市場規模予測 2021年-2026年（病院、家庭、その他） ・北米のコレステロール降下薬市場分析：米国、カナダ ・ヨーロッパのコレステロール降下薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのコレステロール降下薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のコレステロール降下薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのコレステロール降下薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Merck、Pfizer、Kowa、Daiichi Sankyo、AbbVie、Novartis、Sanofi、Amgen、Bristol-Myers Squibb ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Cholesterol-Lowering Drugs Market
The global Cholesterol-Lowering Drugs market size is projected to reach US$ 17960 million by 2026, from US$ 17440 million in 2020, at a CAGR of 2.8%% during 2021-2026.
Global Cholesterol-Lowering Drugs Scope and Market Size
Cholesterol-Lowering Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cholesterol-Lowering Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cholesterol-Lowering Drugs market is segmented into
Statins
Cholesterol Absorption Inhibitors
Fibrates
PCSK9 Inhibitors
Segment by Application, the Cholesterol-Lowering Drugs market is segmented into
Hospital
Household
Other
Regional and Country-level Analysis
The Cholesterol-Lowering Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cholesterol-Lowering Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cholesterol-Lowering Drugs Market Share Analysis
Cholesterol-Lowering Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cholesterol-Lowering Drugs business, the date to enter into the Cholesterol-Lowering Drugs market, Cholesterol-Lowering Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
Merck
Pfizer
Kowa
Daiichi Sankyo
AbbVie
Novartis
Sanofi
Amgen
Bristol-Myers Squibb
1 Study Coverage
1.1 Cholesterol-Lowering Drugs Product Introduction
1.2 Market Segments
1.3 Key Cholesterol-Lowering Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cholesterol-Lowering Drugs Market Size Growth Rate by Type
1.4.2 Statins
1.4.3 Cholesterol Absorption Inhibitors
1.4.4 Fibrates
1.4.5 PCSK9 Inhibitors
1.5 Market by Application
1.5.1 Global Cholesterol-Lowering Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Household
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cholesterol-Lowering Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cholesterol-Lowering Drugs Revenue 2015-2026
2.1.2 Global Cholesterol-Lowering Drugs Sales 2015-2026
2.2 Global Cholesterol-Lowering Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cholesterol-Lowering Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cholesterol-Lowering Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cholesterol-Lowering Drugs Competitor Landscape by Players
3.1 Cholesterol-Lowering Drugs Sales by Manufacturers
3.1.1 Cholesterol-Lowering Drugs Sales by Manufacturers (2015-2020)
3.1.2 Cholesterol-Lowering Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Cholesterol-Lowering Drugs Revenue by Manufacturers
3.2.1 Cholesterol-Lowering Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Cholesterol-Lowering Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cholesterol-Lowering Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cholesterol-Lowering Drugs Revenue in 2019
3.2.5 Global Cholesterol-Lowering Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cholesterol-Lowering Drugs Price by Manufacturers
3.4 Cholesterol-Lowering Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cholesterol-Lowering Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cholesterol-Lowering Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cholesterol-Lowering Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cholesterol-Lowering Drugs Market Size by Type (2015-2020)
4.1.1 Global Cholesterol-Lowering Drugs Sales by Type (2015-2020)
4.1.2 Global Cholesterol-Lowering Drugs Revenue by Type (2015-2020)
4.1.3 Cholesterol-Lowering Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cholesterol-Lowering Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Cholesterol-Lowering Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Cholesterol-Lowering Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Cholesterol-Lowering Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cholesterol-Lowering Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cholesterol-Lowering Drugs Market Size by Application (2015-2020)
5.1.1 Global Cholesterol-Lowering Drugs Sales by Application (2015-2020)
5.1.2 Global Cholesterol-Lowering Drugs Revenue by Application (2015-2020)
5.1.3 Cholesterol-Lowering Drugs Price by Application (2015-2020)
5.2 Cholesterol-Lowering Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Cholesterol-Lowering Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Cholesterol-Lowering Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Cholesterol-Lowering Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cholesterol-Lowering Drugs by Country
6.1.1 North America Cholesterol-Lowering Drugs Sales by Country
6.1.2 North America Cholesterol-Lowering Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cholesterol-Lowering Drugs Market Facts & Figures by Type
6.3 North America Cholesterol-Lowering Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Cholesterol-Lowering Drugs by Country
7.1.1 Europe Cholesterol-Lowering Drugs Sales by Country
7.1.2 Europe Cholesterol-Lowering Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cholesterol-Lowering Drugs Market Facts & Figures by Type
7.3 Europe Cholesterol-Lowering Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cholesterol-Lowering Drugs by Region
8.1.1 Asia Pacific Cholesterol-Lowering Drugs Sales by Region
8.1.2 Asia Pacific Cholesterol-Lowering Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cholesterol-Lowering Drugs Market Facts & Figures by Type
8.3 Asia Pacific Cholesterol-Lowering Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cholesterol-Lowering Drugs by Country
9.1.1 Latin America Cholesterol-Lowering Drugs Sales by Country
9.1.2 Latin America Cholesterol-Lowering Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cholesterol-Lowering Drugs Market Facts & Figures by Type
9.3 Central & South America Cholesterol-Lowering Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cholesterol-Lowering Drugs by Country
10.1.1 Middle East and Africa Cholesterol-Lowering Drugs Sales by Country
10.1.2 Middle East and Africa Cholesterol-Lowering Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cholesterol-Lowering Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Cholesterol-Lowering Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cholesterol-Lowering Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description and Business Overview
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Cholesterol-Lowering Drugs Products Offered
11.2.5 Merck Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Cholesterol-Lowering Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Kowa
11.4.1 Kowa Corporation Information
11.4.2 Kowa Description and Business Overview
11.4.3 Kowa Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Kowa Cholesterol-Lowering Drugs Products Offered
11.4.5 Kowa Related Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Description and Business Overview
11.5.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Daiichi Sankyo Cholesterol-Lowering Drugs Products Offered
11.5.5 Daiichi Sankyo Related Developments
11.6 AbbVie
11.6.1 AbbVie Corporation Information
11.6.2 AbbVie Description and Business Overview
11.6.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AbbVie Cholesterol-Lowering Drugs Products Offered
11.6.5 AbbVie Related Developments
11.7 Novartis
11.7.1 Novartis Corporation Information
11.7.2 Novartis Description and Business Overview
11.7.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Novartis Cholesterol-Lowering Drugs Products Offered
11.7.5 Novartis Related Developments
11.8 Sanofi
11.8.1 Sanofi Corporation Information
11.8.2 Sanofi Description and Business Overview
11.8.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Sanofi Cholesterol-Lowering Drugs Products Offered
11.8.5 Sanofi Related Developments
11.9 Amgen
11.9.1 Amgen Corporation Information
11.9.2 Amgen Description and Business Overview
11.9.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Amgen Cholesterol-Lowering Drugs Products Offered
11.9.5 Amgen Related Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Corporation Information
11.10.2 Bristol-Myers Squibb Description and Business Overview
11.10.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Bristol-Myers Squibb Cholesterol-Lowering Drugs Products Offered
11.10.5 Bristol-Myers Squibb Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cholesterol-Lowering Drugs Products Offered
11.1.5 AstraZeneca Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cholesterol-Lowering Drugs Market Estimates and Projections by Region
12.1.1 Global Cholesterol-Lowering Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Cholesterol-Lowering Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Cholesterol-Lowering Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Cholesterol-Lowering Drugs Sales Forecast (2021-2026)
12.2.2 North America: Cholesterol-Lowering Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Cholesterol-Lowering Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Cholesterol-Lowering Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Cholesterol-Lowering Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Cholesterol-Lowering Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Cholesterol-Lowering Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cholesterol-Lowering Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cholesterol-Lowering Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cholesterol-Lowering Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cholesterol-Lowering Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Cholesterol-Lowering Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Cholesterol-Lowering Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Cholesterol-Lowering Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Cholesterol-Lowering Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cholesterol-Lowering Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cholesterol-Lowering Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cholesterol-Lowering Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cholesterol-Lowering Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cholesterol-Lowering Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cholesterol-Lowering Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cholesterol-Lowering Drugs Market Segments
Table 2. Ranking of Global Top Cholesterol-Lowering Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cholesterol-Lowering Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Statins
Table 5. Major Manufacturers of Cholesterol Absorption Inhibitors
Table 6. Major Manufacturers of Fibrates
Table 7. Major Manufacturers of PCSK9 Inhibitors
Table 8. Global Cholesterol-Lowering Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 9. Global Cholesterol-Lowering Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 10. Global Cholesterol-Lowering Drugs Sales by Regions 2015-2020 (K MT)
Table 11. Global Cholesterol-Lowering Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Cholesterol-Lowering Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Cholesterol-Lowering Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 14. Global Cholesterol-Lowering Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Cholesterol-Lowering Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Cholesterol-Lowering Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cholesterol-Lowering Drugs as of 2019)
Table 17. Cholesterol-Lowering Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Cholesterol-Lowering Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Cholesterol-Lowering Drugs Price (2015-2020) (USD/MT)
Table 20. Cholesterol-Lowering Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Cholesterol-Lowering Drugs Product Type
Table 22. Date of International Manufacturers Enter into Cholesterol-Lowering Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 25. Global Cholesterol-Lowering Drugs Sales Share by Type (2015-2020)
Table 26. Global Cholesterol-Lowering Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Cholesterol-Lowering Drugs Revenue Share by Type (2015-2020)
Table 28. Cholesterol-Lowering Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 29. Global Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 30. Global Cholesterol-Lowering Drugs Sales Share by Application (2015-2020)
Table 31. North America Cholesterol-Lowering Drugs Sales by Country (2015-2020) (K MT)
Table 32. North America Cholesterol-Lowering Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Cholesterol-Lowering Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Cholesterol-Lowering Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 36. North America Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 38. North America Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Cholesterol-Lowering Drugs Sales by Country (2015-2020) (K MT)
Table 40. Europe Cholesterol-Lowering Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Cholesterol-Lowering Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Cholesterol-Lowering Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 44. Europe Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 46. Europe Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Cholesterol-Lowering Drugs Sales by Region (2015-2020) (K MT)
Table 48. Asia Pacific Cholesterol-Lowering Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Cholesterol-Lowering Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Cholesterol-Lowering Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 52. Asia Pacific Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 54. Asia Pacific Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Cholesterol-Lowering Drugs Sales by Country (2015-2020) (K MT)
Table 56. Latin America Cholesterol-Lowering Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Cholesterol-Lowering Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Cholesterol-Lowering Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 60. Latin America Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 62. Latin America Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Cholesterol-Lowering Drugs Sales by Country (2015-2020) (K MT)
Table 64. Middle East and Africa Cholesterol-Lowering Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Cholesterol-Lowering Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Cholesterol-Lowering Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Cholesterol-Lowering Drugs Sales by Type (2015-2020) (K MT)
Table 68. Middle East and Africa Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Cholesterol-Lowering Drugs Sales by Application (2015-2020) (K MT)
Table 70. Middle East and Africa Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Table 71. AstraZeneca Corporation Information
Table 72. AstraZeneca Description and Major Businesses
Table 73. AstraZeneca Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 74. AstraZeneca Product
Table 75. AstraZeneca Recent Development
Table 76. Merck Corporation Information
Table 77. Merck Description and Major Businesses
Table 78. Merck Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. Merck Product
Table 80. Merck Recent Development
Table 81. Pfizer Corporation Information
Table 82. Pfizer Description and Major Businesses
Table 83. Pfizer Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Pfizer Product
Table 85. Pfizer Recent Development
Table 86. Kowa Corporation Information
Table 87. Kowa Description and Major Businesses
Table 88. Kowa Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Kowa Product
Table 90. Kowa Recent Development
Table 91. Daiichi Sankyo Corporation Information
Table 92. Daiichi Sankyo Description and Major Businesses
Table 93. Daiichi Sankyo Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Daiichi Sankyo Product
Table 95. Daiichi Sankyo Recent Development
Table 96. AbbVie Corporation Information
Table 97. AbbVie Description and Major Businesses
Table 98. AbbVie Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. AbbVie Product
Table 100. AbbVie Recent Development
Table 101. Novartis Corporation Information
Table 102. Novartis Description and Major Businesses
Table 103. Novartis Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Novartis Product
Table 105. Novartis Recent Development
Table 106. Sanofi Corporation Information
Table 107. Sanofi Description and Major Businesses
Table 108. Sanofi Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Sanofi Product
Table 110. Sanofi Recent Development
Table 111. Amgen Corporation Information
Table 112. Amgen Description and Major Businesses
Table 113. Amgen Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. Amgen Product
Table 115. Amgen Recent Development
Table 116. Bristol-Myers Squibb Corporation Information
Table 117. Bristol-Myers Squibb Description and Major Businesses
Table 118. Bristol-Myers Squibb Cholesterol-Lowering Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. Bristol-Myers Squibb Product
Table 120. Bristol-Myers Squibb Recent Development
Table 121. Global Cholesterol-Lowering Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 122. Global Cholesterol-Lowering Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 123. Global Cholesterol-Lowering Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 124. Global Cholesterol-Lowering Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 125. North America: Cholesterol-Lowering Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 126. North America: Cholesterol-Lowering Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Europe: Cholesterol-Lowering Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 128. Europe: Cholesterol-Lowering Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Asia Pacific: Cholesterol-Lowering Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 130. Asia Pacific: Cholesterol-Lowering Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 131. Latin America: Cholesterol-Lowering Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 132. Latin America: Cholesterol-Lowering Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Middle East and Africa: Cholesterol-Lowering Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 134. Middle East and Africa: Cholesterol-Lowering Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 136. Key Challenges
Table 137. Market Risks
Table 138. Main Points Interviewed from Key Cholesterol-Lowering Drugs Players
Table 139. Cholesterol-Lowering Drugs Customers List
Table 140. Cholesterol-Lowering Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Cholesterol-Lowering Drugs Product Picture
Figure 2. Global Cholesterol-Lowering Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Statins Product Picture
Figure 4. Cholesterol Absorption Inhibitors Product Picture
Figure 5. Fibrates Product Picture
Figure 6. PCSK9 Inhibitors Product Picture
Figure 7. Global Cholesterol-Lowering Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Household
Figure 10. Other
Figure 11. Cholesterol-Lowering Drugs Report Years Considered
Figure 12. Global Cholesterol-Lowering Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Cholesterol-Lowering Drugs Sales 2015-2026 (K MT)
Figure 14. Global Cholesterol-Lowering Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Cholesterol-Lowering Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Cholesterol-Lowering Drugs Sales Market Share by Region in 2019
Figure 17. Global Cholesterol-Lowering Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Cholesterol-Lowering Drugs Revenue Market Share by Region in 2019
Figure 19. Global Cholesterol-Lowering Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Cholesterol-Lowering Drugs Revenue in 2019
Figure 21. Cholesterol-Lowering Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Cholesterol-Lowering Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Cholesterol-Lowering Drugs Sales Market Share by Type in 2019
Figure 24. Global Cholesterol-Lowering Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Cholesterol-Lowering Drugs Revenue Market Share by Type in 2019
Figure 26. Global Cholesterol-Lowering Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Cholesterol-Lowering Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Cholesterol-Lowering Drugs Sales Market Share by Application in 2019
Figure 29. Global Cholesterol-Lowering Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Cholesterol-Lowering Drugs Revenue Market Share by Application in 2019
Figure 31. North America Cholesterol-Lowering Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 32. North America Cholesterol-Lowering Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Cholesterol-Lowering Drugs Sales Market Share by Country in 2019
Figure 34. North America Cholesterol-Lowering Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. U.S. Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 38. Canada Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Cholesterol-Lowering Drugs Market Share by Type in 2019
Figure 40. North America Cholesterol-Lowering Drugs Market Share by Application in 2019
Figure 41. Europe Cholesterol-Lowering Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 42. Europe Cholesterol-Lowering Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Cholesterol-Lowering Drugs Sales Market Share by Country in 2019
Figure 44. Europe Cholesterol-Lowering Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. Germany Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. France Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. U.K. Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Italy Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 54. Russia Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Cholesterol-Lowering Drugs Market Share by Type in 2019
Figure 56. Europe Cholesterol-Lowering Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Cholesterol-Lowering Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 58. Asia Pacific Cholesterol-Lowering Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Cholesterol-Lowering Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Cholesterol-Lowering Drugs Revenue Market Share by Region in 2019
Figure 61. China Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. China Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. Japan Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. South Korea Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. India Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Australia Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Taiwan Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Indonesia Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Thailand Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Malaysia Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Philippines Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 82. Vietnam Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Cholesterol-Lowering Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Cholesterol-Lowering Drugs Market Share by Application in 2019
Figure 85. Latin America Cholesterol-Lowering Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 86. Latin America Cholesterol-Lowering Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Cholesterol-Lowering Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Cholesterol-Lowering Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Mexico Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Brazil Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 94. Argentina Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Cholesterol-Lowering Drugs Market Share by Type in 2019
Figure 96. Latin America Cholesterol-Lowering Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Cholesterol-Lowering Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 98. Middle East and Africa Cholesterol-Lowering Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Cholesterol-Lowering Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Cholesterol-Lowering Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Turkey Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. Saudi Arabia Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Cholesterol-Lowering Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 106. U.A.E Cholesterol-Lowering Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Cholesterol-Lowering Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Cholesterol-Lowering Drugs Market Share by Application in 2019
Figure 109. North America Cholesterol-Lowering Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. North America Cholesterol-Lowering Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Cholesterol-Lowering Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Europe Cholesterol-Lowering Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Cholesterol-Lowering Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Asia Pacific Cholesterol-Lowering Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Cholesterol-Lowering Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Latin America Cholesterol-Lowering Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Cholesterol-Lowering Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. Middle East and Africa Cholesterol-Lowering Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
コレステロール低下生物学的薬剤の世界市場（～2026年） The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad chol…- コレステロール検査サービスの世界市場（～2026年） Market Analysis and Insights: Global Cholesterol Testing Services Market The global Cholesterol Testing Services market size is projected to reach US$ 12340 million by 2026, from US$ 11770 million in 2020, at a CAGR of 4.4%% during 2021-2026. Global Cholesterol Testing Services Scope and Market Size…
- コレステロール薬の世界市場（～2026年） Market Analysis and Insights: Global Cholesterol Medicines Market The global Cholesterol Medicines market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cholesterol Medicines Scope and Market Size Cholesterol Medicines marke…
- 脂質低下剤の世界市場（～2026年） Market Analysis and Insights: Global Lipid-lowering Agent Market The global Lipid-lowering Agent market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Lipid-lowering Agent Scope and Market Size Lipid-lowering Agent market is…
- 高脂血症処方薬の世界市場（～2026年） Market Analysis and Insights: Global Hyperlipidemia Prescription Drugs Market The global Hyperlipidemia Prescription Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hyperlipidemia Prescription Drugs Scope and Mar…